NULISA CNS Disease Biomarker Platform
- The only high-plex, high sensitivity platform for investigation of biomarkers of neurodegenerative diseases and treatment response
- NULISA™ combines ultra-sensitive femtogram level detection with barcodebased high-plex biomarker analysis
- The NULISA CNS Disease Panel is unique in enabling investigation of hundreds of proteins involved in neuroinflammation, vascular, and synaptic dysfunction, and proteinopathies
- NULISA offers the unique ability to translate multiplexed biomarker profiling for discoveries to single and low-plex biomarker assays run with the same assay on the same instrument
- NULISA single-, low-, and high-plex assays all run fully automated on the ARGO HT System
- NULISA CNS Disease Panel 120 and Inflammation Panel 250 are used for exploratory clinical research into therapeutic effects on neurodegenerative disease processes
- NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA